Gensight Biologics S.a annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Depreciation & Amortization Growth & History (SIGHT)
Gensight Biologics S.a's depreciation and amortization was €465,000 for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €465,000 | −€594,000 | −56.09% |
| 2024 | 2024-12-31 | €1.1M | −€1.1M | −51.40% |
| 2023 | 2023-12-31 | €2.2M | €1.1M | +105.37% |
| 2022 | 2022-12-31 | €1.1M | €133,000 | +14.33% |
| 2021 | 2021-12-31 | €928,000 | €2,000 | +0.22% |
| 2020 | 2020-12-31 | €926,000 | — | — |
Gensight Biologics S.a depreciation and amortization trends
Over the last five fiscal years, Gensight Biologics S.a's depreciation and amortization decreased from €926,000 to €465,000, a change of −€461,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...